力生制药（002393）公告，预计2025年上半年净利润为33000-3.55亿元，比上年同期的1.02亿元上升 222.42%-246.85%。 ...

Core Insights - Diuretics are essential medications for treating conditions like hypertension and heart failure, with a growing market demand driven by increasing cardiovascular disease prevalence in China [1][7][16] Industry Overview - The current landscape of cardiovascular diseases in China is severe, with 330 million patients, including 8.9 million with heart failure and 245 million with hypertension [1][7] - The diuretic market in China is projected to reach 4.22 billion yuan in 2024, reflecting an 11% year-on-year growth [1][7] - Hospitals are the primary sales channel for diuretics, accounting for over 85% of sales, with hospital sales expected to reach 3.63 billion yuan in 2024, a 13% increase [9][11] Market Dynamics - The competitive landscape of the diuretic market is fragmented, with numerous manufacturers. The top ten companies hold a combined market share of 50% [13][15] - Notable domestic companies include Guilin Pharmaceutical, Tianjin Lisheng, Nanjing Haichen, and Hangzhou Minsheng [13][15] Product Classification - Diuretics are categorized into four main types: 1. **Loop Diuretics** (e.g., Furosemide, Torasemide) - affect both urine dilution and concentration [4] 2. **Thiazide Diuretics** (e.g., Hydrochlorothiazide, Indapamide) - primarily affect urine dilution [4] 3. **Potassium-Sparing Diuretics** (e.g., Amiloride, Spironolactone) - reduce potassium excretion [4] 4. **Carbonic Anhydrase Inhibitors** (e.g., Acetazolamide) - have weak effects and are rarely used [4] Future Trends - The aging population and rising chronic disease rates are significant factors driving the growth of the diuretic market [16] - There is a shift in hypertension treatment from monotherapy to combination therapy, with single-pill combinations becoming more prevalent [17] - Innovations in diuretic development are focused on creating more selective agents to minimize side effects like electrolyte imbalances and metabolic issues [18]

Group 1 - The company, Tianjin Lifescience Pharmaceutical Co., Ltd., is required to pay a total of approximately 35.11 million yuan in tax and late fees due to local tax inspections and self-examinations [1] - The breakdown of the payment includes approximately 30.88 million yuan for income tax and late fees, and 4.23 million yuan for value-added tax and late fees [1] - All tax payments and late fees have been fully paid by the company [1] Group 2 - The tax payment and late fees will be recorded in the company's 2025 financial results, expected to reduce the net profit attributable to shareholders by 35.11 million yuan [2] - The management of the company is taking this matter seriously and will enhance tax management and conduct ongoing tax training to protect the interests of the company and its shareholders [2]

证券代码：002393 证券简称：力生制药 公告编号：2025-045 天津力生制药股份有限公司 关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"）根据当地税务检查和企业自查情况， 需补缴税款及滞纳金共计约3,511万元。现将有关情况公告如下: 一、基本情况 根据国家税务总局天津市西青税务局对公司检查情况，以及公司自查情况，公司应补 缴税款及滞纳金等共计约3,511万元，其中：需补缴所得税及滞纳金3,088万元，需补缴增 值税及滞纳金423万元，本次不涉及行政处罚。上述税款及滞纳金目前已全部缴纳完毕。 二、对公司的影响及风险提示 根据《企业会计准则第28号--会计政策、会计估计变更和差错更正》，上述补缴税款及 滞纳金事项不属于前期会计差错，不涉及前期财务数据追溯调整。公司补缴的税款及滞纳 金将计入2025年当期损益，预计将减少公司2025年度归属于上市公司股东的净利润3,511 万元，具体影响金额最终以会计师事务所审计数据为准。 公司管理层对上述事项高度重视，将进一步加强税务管理，持续开展税务专业培 ...

力生制药（002393）公告，根据当地税务检查和企业自查，需补缴税款及滞纳金共计约3511万元。其 中，需补缴所得税及滞纳金3088万元，需补缴增值税及滞纳金423万元。本次不涉及行政处罚。上述税 款及滞纳金目前已全部缴纳完毕。补缴的税款及滞纳金将计入2025年当期损益，预计将减少公司2025年 度归属于上市公司股东的净利润3511万元。 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-044 天津力生制药股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事 会第五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年 使用闲置自有资金进行现金管理额度的议案》，同意公司使用额度不超过人民币10亿元闲 置自有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品， 包括但不限于通过银行、证券等专业理财机构购买的理财产品，期限不超过股东大会批准 之日起12个月，在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月 21日在巨潮资讯网(www.cninfo.com.cn）披露的《关于公司2025年使用闲置自有资金进行 现金管理额度的公告》（公告编号：2025-024）。 一、本次进行现金管理购买理财产品情况 公司以自有资金共计5,000万元人民币在兴业银行股份有限公司天津分行（以下简称"兴 ...

证券时报·数据宝统计显示，常山药业所属的医药生物行业，目前整体跌幅为0.46%，行业内，目前股价 上涨的有80只，涨幅居前的有爱朋医疗、创新医疗、永安药业等，涨幅分别为11.58%、8.31%、 7.35%。股价下跌的有399只，跌幅居前的有广生堂、千红制药、力生制药等，跌幅分别为7.95%、 4.74%、4.39%。 两融数据显示，该股最新（6月17日）两融余额为14.03亿元，其中，融资余额为14.03亿元，近10日增加 4.15亿元，环比增长42.06%。 常山药业股价再创历史新高，该股近期呈不断突破新高之势，近一个月累计有10个交易日股价刷新历史 纪录。截至09:36，该股目前上涨3.20%，股价报54.48元，成交823.60万股，成交金额4.41亿元，换手率 0.90%，该股最新A股总市值达500.70亿元，该股A股流通市值499.08亿元。 公司6月11日在交易所互动平台披露，截至最新（6月10日）股东户数为50546户，较上期（5月31日）增 加7415户，环比增长17.19%。这是该股股东户数连续第2期增长，也就是说筹码呈持续分散趋势。 公司发布的一季报数据显示，一季度公司共实现营业收入2. ...

Core Viewpoint - Lisheng Pharmaceutical (002393) has seen a significant increase in stock price, reaching a nearly one-year high, and is actively managing idle funds through short-term financial products [1][2]. Company Stock Performance - As of June 13, 2025, Lisheng Pharmaceutical's stock closed at 22.11 yuan, up 13.79% from the previous week [1]. - The stock reached a peak of 22.11 yuan during the week and a low of 19.5 yuan [1]. - The company's current market capitalization is 5.698 billion yuan, ranking 83rd out of 150 in the chemical pharmaceutical sector and 2608th out of 5150 in the A-share market [1]. Company Announcements - Lisheng Pharmaceutical announced the use of up to 1 billion yuan of idle self-owned funds for cash management, investing in short-term financial products with a maturity of no more than 12 months [2]. - The company has invested 50 million yuan in financial products from Industrial Bank, including 10 million yuan in a flexible income product and 40 million yuan in a stable income product, with expected yields of approximately 2% and 2.2% respectively [2]. - The total amount of idle self-owned funds invested in financial products as of the announcement date is 639 million yuan, which is within the authorized limit [2]. Fund Management - Lisheng Pharmaceutical also plans to use up to 600 million yuan of idle raised funds for cash management, investing in short-term financial products with a maturity of no more than 12 months [2]. - The company has invested 50 million yuan in structured deposits from Industrial Bank, with an expected annual yield of 1.20%-1.80% [2]. - The total amount of idle raised funds invested in financial products as of the announcement date is 85 million yuan, also within the approved limit [2].

今日，A股三大指数回调。 盘面上， 蚂蚁金服概念股活跃，正元智慧（300645）午后一分钟内直线拉升，实现"20CM"涨停；A股 油气开采及服务板块表现强势，科力股份"30CM"涨停，通源石油"20CM"涨停。 美容护理、互联网电商、影视院线板块回调明显；昨日大涨的创新药板块今日下跌， 力生制药 （002393）午后逆势涨停。 今日，数字货币概念股局部回暖，蚂蚁金服概念股活跃。 正元智慧（300645）午后在一分钟内直线拉 升，实现"20CM"涨停；吉大正元收获"2连板"，协鑫能科一字涨停，金时科技尾盘涨停。 | 金时科技 | | 13.96 +10.01% +13.13% | | | --- | --- | --- | --- | | 002951 | | | | | 人气龙头1 领涨龙头1 | 首板 最终涨停14:56 | | | | 华信永道 | 68.95 | +6.00% +17.48% | | | 837592 | | | | | 朗新集团 | 17.06 | +4.66% +5.18% | | | 300682 | | | | | 恒生电子 | 27.75 | +3.85% | +3.24% | ...

今日，A股三大指数回调。 盘面上， 蚂蚁金服概念股活跃，正元智慧（300645）午后一分钟内直线拉升，实现"20CM"涨停；A股 油气开采及服务板块表现强势，科力股份"30CM"涨停，通源石油"20CM"涨停。 力生制药日前在深交所互动易平台表示，公司近年来实施内生外引并举战略，通过自主研发、合作开 发、许可引进、CMO孵化等方式，推进高端仿制药、创新药、合成生物学、细胞与基因治疗等业务布 局，向更高价值链延伸。推进"原料药+制剂"一体化，向技术壁垒高、附加值高的特色品种延伸。公司 研发强度持续保持7%以上，研发成果加速涌现。2022年获得批件6个，2023年获得批件4个，2024年获 得批件16个，创历史新高。 力生制药2024年年报显示，公司作为化学制药领域少数中华老字号品牌之一，专注于医药产品研发、生 产和销售，主要产品包括寿比山吲达帕胺片、三鱼氨酚咖匹林片等。 蚂蚁金服概念股活跃 今日，数字货币概念股局部回暖，蚂蚁金服概念股活跃。 正元智慧（300645）午后在一分钟内直线拉 升，实现"20CM"涨停；吉大正元收获"2连板"，协鑫能科一字涨停，金时科技尾盘涨停。 美容护理、互联网电商、影视院线板块回调 ...